Ypsomed doubles profits and confirms outlook

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 15.11.2023, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trend and achieved consolidated sales of CHF 255.4 million in the first six months of the 2023/24 financial year (previous year: CHF 244.2 million). 

Lue lisää...

mylife Loop improves health of pregnant women with type 1 diabetes and their babies

Press Releases Ypsomed Group

Burgdorf – Pregnant women with type 1 diabetes and their babies benefit from treatment with a hybrid closed loop system based on the CamAPS FX algorithm. This is demonstrated by the AiDAPT clinical study, which clinical outcomes were published in the New England Journal of Medicine and the experience of the pregnant women in Diabetes Technology and Therapeutics, both on 5 October 2023. The algorithm of Ypsomed's mylife Loop, the CamAPS FX app is the only automated insulin delivery (AID) algorithm approved for pregnant women with type 1 diabetes.

Topics:
Innovation & Digital Health

Lue lisää...

Ypsomed enhances self-injection device platforms with integrated human factors services

Press Releases Ypsomed Group

Burgdorf – Ypsomed announces new Human Factors (HF) services for its pharmaceutical partners to reinforce its position as a leading developer and manufacturer of self-injection solutions. By enhancing its device platform offering with integrated end-to-end HF services, Ypsomed is championing a comprehensive service approach to combination product development that de-risks regulatory approval and expedites time-to-market for its partners. To do so, Ypsomed has entered into a strategic partnership with Interface Analysis Associates LLC (IAA), a leading HF service provider with long-standing expertise in supporting the pharmaceutical industry along the full combination product development journey. 

Topics:
Platforms & Operational Excellence

Lue lisää...

Samuel Künzli succeeds Niklaus Ramseier as CFO and member of the Executive Board

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf, 29.09.2023, 7:00 a.m. – Ypsomed (SIX: YPSN) announces a change in its Executive Board. After more than twenty years, Niklaus Ramseier will hand over his functions as Chief Financial Officer (CFO) on 31 March 2024 and will continue to be available to the company for strategic projects. His successor is Samuel Künzli, who will start his position as CFO on 01 April 2024.

Lue lisää...

Ypsomed concludes a long-term supply agreement for large quantities of autoinjectors

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) has concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors. The autoinjectors will be used to administer drugs for the self-treatment in various metabolic indications. Ypsomed is in the process of substantially increasing its annual manufacturing capacity in several steps until 2031.

Lue lisää...